title: Psoriasis Therapy: Breakthroughs in Pharmacogenomics or in Pharmacology?
abstract: As the cost of psoriasis therapies skyrockets, it becomes increasingly important to find biomarkers that predict which patients will respond to expensive medications. The ability to predict response to a specific therapy is particularly important for medications that are effective in only a small portion of the population. As we develop medications that clear most patients, the need for a predictive biomarker diminishes. Nevertheless, the importance of pharmacogenomics is likely to increase as the cost of drugs continues to rise.
authors.affiliation: Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: lebwohl@aol.com.
authors.forename: Mark
authors.initials: M
authors.lastname: Lebwohl
mesh_terms: D003879:Dermatologic Agents / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D017277:Drug Approval; D005260:Female; D005819:Genetic Markers; D006801:Humans; D008297:Male; D020380:Needs Assessment; D010597:Pharmacogenetics / Q000379:methods*; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics*; D014481:United States
chemical_list: D003879:Dermatologic Agents; D005819:Genetic Markers